Consideration for safety assessment of innate immunity activation by oligonucleotide therapeutics

Abstract

In recent years, oligonucleotide therapeutics have been attracting attention as a new modality to treat intractable diseases and genetic disorders. Oligonucleotide therapeutics differ from conventional drugs that target proteins in that they are able to regulate the gene expression at the RNA level, a feature that has led to their rapid development and clinical use over the past several years. In this symposium, I would like to outline the basics of oligonucleotide therapeutics and discuss methods to evaluate the activation of innate immunity by oligonucleotide therapeutics.